Becker's Healthcare July 3, 2024
Jakob Emerson

The world of GLP-1s is quickly evolving with new clinical research, insurance coverage decisions, and emerging products on the market.

To dive into these issues, Becker’s sat down with Christine Ren Fielding, MD, professor of surgery at NYU School of Medicine, director of the NYU Langone Weight Management Program and chief of the system’s division of bariatric surgery.

Question: The GLP-1 market is facing low supply and competition right now, alongside high consumer demand and pricing — what are you seeing and hearing among your patients?

Dr. Christine Ren Fielding: The challenges are very real and very significant because of demand that has always been there. This tremendous demand is merely a reflection of the severity of our country’s obesity...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Health System / Hospital, Insurance, Interview / Q&A, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
Gene Therapy for Cardiomyopathies Presents Promising Alternative to Current Treatment
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions

Share This Article